Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ6 | P48051 | 14/20 | 0.49 |
| ▸ | KCNJ3 | P48549 | 14/20 | 0.49 |
| ▸ | KCNJ5 | P48544 | 11/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.46 |
| ▸ | BRAF | P15056 | 3/20 | 0.43 |
| ▸ | RAF1 | P04049 | 2/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2083312 | 0.87 | FLT3 (0.52) | NTRK1BRAFMAPK14 | |
| SCHEMBL13859627 | 0.75 | KCNJ6 (0.69) | KCNJ6KCNJ3KCNJ5NTRK1BRAF | |
| SCHEMBL4303949 | 0.71 | KCNJ6 (0.58) | KCNJ6KCNJ3KCNJ5NTRK1BRAF | |
| SCHEMBL2083435 | 0.68 | MAPK14 (0.47) | BRAFRAF1MAPK14 | |
| SCHEMBL2245642 | 0.68 | KCNJ6 (0.60) | KCNJ6KCNJ3KCNJ5BRAFRAF1 | |
| SCHEMBL2241149 | 0.67 | MAPK14 (0.62) | KCNJ6KCNJ3KCNJ5NTRK1BRAF | |
| SCHEMBL2243743 | 0.67 | KCNJ6 (0.58) | KCNJ6KCNJ3KCNJ5BRAFRAF1 | |
| SCHEMBL2243426 | 0.65 | MAPK14 (0.62) | KCNJ6KCNJ3KCNJ5NTRK1BRAF | |
| SCHEMBL2082265 | 0.64 | BRAF (0.57) | NTRK1BRAFMAPK14 | |
| SCHEMBL2240721 | 0.64 | KCNJ6 (0.58) | KCNJ6KCNJ3KCNJ5BRAFRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1835934-A2 | ENZYME MODULATORS AND TREATMENTS | Deciphera Pharmaceuticals, LLC (US) | 2007-09-26 | — | — | EP | claimed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | claimed |
| WO-2006071940-A2 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2006-07-06 | — | — | WO | claimed |
| US-8163756-B2 | For example,1-(3-t-butyl-1- (1,2,3,4-tetrahydro- isoquinolin-6-yl)-1H- pyrazol-5-yl)-3-(3- cyanophenyl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
| EP-1835934-A2 | ENZYME MODULATORS AND TREATMENTS | Deciphera Pharmaceuticals, LLC (US) | 2007-09-26 | — | — | EP | disclosed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | disclosed |
| WO-2006071940-A2 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078121-A1 | Enzyme modulators and treatments | ABL1, ABL2, LCK | KCNJ6 4192/4885KCNJ3 4273/4885KCNJ5 4319/4885 |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | ABL2, BRAF, MAP3K1 | KCNJ6 3243/4885KCNJ3 3372/4885KCNJ5 3284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.